CO2023017669A2 - Terapia combinada anti-vhc ventajosa - Google Patents

Terapia combinada anti-vhc ventajosa

Info

Publication number
CO2023017669A2
CO2023017669A2 CONC2023/0017669A CO2023017669A CO2023017669A2 CO 2023017669 A2 CO2023017669 A2 CO 2023017669A2 CO 2023017669 A CO2023017669 A CO 2023017669A CO 2023017669 A2 CO2023017669 A2 CO 2023017669A2
Authority
CO
Colombia
Prior art keywords
compound
combination therapy
advantageous anti
hcv combination
pharmaceutically acceptable
Prior art date
Application number
CONC2023/0017669A
Other languages
English (en)
Inventor
Jean-Pierre Sommadossi
Adel Moussa
Keith M Pietropaolo
xiao-jian Zhou
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/034083 external-priority patent/WO2022266497A1/en
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of CO2023017669A2 publication Critical patent/CO2023017669A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una combinación farmacéutica sinérgica del Compuesto 1 o una sal farmacéuticamente aceptable del mismo (por ejemplo, el Compuesto 1-A) y el Compuesto 2 o una sal farmacéuticamente aceptable del mismo, así como sus usos para tratar la hepatitis C o una afección relacionada con la hepatitis C, así como los métodos para la fabricación de la combinación farmacéutica: : Compuesto 1 Compuesto 1-A Compuesto 2
CONC2023/0017669A 2021-06-17 2023-12-18 Terapia combinada anti-vhc ventajosa CO2023017669A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163212047P 2021-06-17 2021-06-17
PCT/US2022/034083 WO2022266497A1 (en) 2021-06-17 2022-06-17 Advantageous anti-hcv combination therapy

Publications (1)

Publication Number Publication Date
CO2023017669A2 true CO2023017669A2 (es) 2023-12-29

Family

ID=84487918

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0017669A CO2023017669A2 (es) 2021-06-17 2023-12-18 Terapia combinada anti-vhc ventajosa

Country Status (11)

Country Link
US (1) US20240148770A1 (es)
EP (1) EP4355319A1 (es)
JP (1) JP2024525164A (es)
KR (1) KR20240022574A (es)
CN (1) CN117500494A (es)
AU (1) AU2022291927A1 (es)
BR (1) BR112023026356A2 (es)
CA (1) CA3174073A1 (es)
CO (1) CO2023017669A2 (es)
IL (1) IL308921A (es)
MX (1) MX2023014898A (es)

Also Published As

Publication number Publication date
CN117500494A (zh) 2024-02-02
KR20240022574A (ko) 2024-02-20
BR112023026356A2 (pt) 2024-03-05
MX2023014898A (es) 2024-04-29
EP4355319A1 (en) 2024-04-24
JP2024525164A (ja) 2024-07-10
US20240148770A1 (en) 2024-05-09
AU2022291927A1 (en) 2024-01-04
CA3174073A1 (en) 2022-12-17
IL308921A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
AR111820A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
CR20140086A (es) Tratamientos de combinación para hepatitis c
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
AR126183A1 (es) Terapia de combinación anti-hcv ventajosa
CO2022001342A2 (es) Agentes antipalúdicos
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR123802A1 (es) Tratamientos del angioedema
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias